The Moderna and Pfizer-BioNTech vaccines offer immunity against COVID-19 for up to six months. To increase protection, getting an updated COVID-19 vaccine is now recommended for everyone six months ...

“The companies told the PTAB in the petitions that Moderna’s patents include ‘unimaginably broad claims directed to a basic idea.’” Patent Trial and Appeal Board (PTAB) docket entries ...

A preprint study posted late last week on the server medRxiv reveals that the current Moderna COVID-19 vaccine is 53% effective against COVID-19–related hospitalization and 39% protective against ...

A German court has ruled that Pfizer and BioNTech violated Moderna's COVID-19 vaccine patent. The court in Duesseldorf stated that Pfizer and BioNTech must provide earning details and compensate ...

Vaccines are a powerful tool of modern medicine, protecting you from diseases that once caused widespread suffering and death ...

Yet vaccines using the new technology of mRNA were developed by Moderna and Pfizer/BioNTech ... simultaneously embracing skepticism of the Covid-19 vaccine development while underscoring the ...

Medical with face mask filling a syringe with vaccine. Covid19 coronavirus vaccine in a syringe. COVID-19 Coronavirus vaccine vials, loopable 3D animation of coronavirus, covid-19 vaccine vials on ...

The public health leader, who was a significant figure during the Covid-19 pandemic, was given the choice to resign or be fired.

As expected, the FDA has moved quickly to grant emergency use authorisation (EUA) to two new-generation COVID-19 mRNA vaccines from Pfizer/BioNTech and Moderna, both targeting the new Omicron ...

Japanese version The data on this "Coronavirus (COVID-19) infections in Japan" page is based on original coverage by the Mainichi Shimbun and press releases from the Ministry of Health ...

A protein-based booster vaccine made by Novavax, which works differently to the Pfizer and Moderna jabs, is also available. Moderna hopes to launch a combined flu and Covid vaccine later in 2025 ...

Shares of Moderna have been volatile at the start of 2025 amid a weak growth outlook. Demand for its COVID-19 vaccine has dropped while sales of its new RSV vaccine have been sluggish. An ...